Genmab — August 2018
-
Jeg ved ikke om det er nyt at MOR202 udvikling i MM bliver stoppet ? https://www.morphosys.com/media-investors/media-center/morphosys-ag-reports-second-quarter-2018-financial-resultshttps://www.morphosys.com/media-investors/media-center/morphosys-ag-reports-second-quarter-2018-financial-results
-
God morgen
-
God morgen.
-
EMA expects a staff loss of about 30% due to Brexit. As if they weren´t slow enough… http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/08/news_detail_002999.jsp&mid=WC0b01ac058004d5c1
-
article on Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States. https://www.ncbi.nlm.nih.gov/pubmed/?term=29290170
-
the article is from januari, but hey, it is Agurketid
full text https://www.jmcp.org/doi/10.18553/jmcp.2018.24.1.29 -
Preclinical evaluation of DuoBody CD3xCD20 to be presented by Ida Hiemstra 14th November 14:35 at conference in Lisbon https://www.pegsummiteurope.com/advancing-bispecifics
-
Optimizing Early Sequencing and Treatment in MM https://www.onclive.com/peer-exchange/myeloma-next-gen-regimens/optimizing-early-sequencing-and-treatment-in-mm
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind